Status: Recruiting
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
Participants needed: 30
Trial details
Phase: Phase 1Age: 40+Biological sex: AllType: InterventionalSponsor: Synusight Biotech (Shanghai) Co., Ltd.Updated: Jun 30, 2026Locations: 2
Eligibility criteria
Sign the informed consent form approved by IEC. [+7]
Being pregnant or lactating. [+10]